Antipodes Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$48.1M	Buy	145,310 +97,424	+203%	+$33.2M	0.93%	42
2025 Q4	$19M	Buy	47,886 +15,930	+50%	+$7.05M	0.4%	51
2025 Q3	$14.6M	Sell	31,956 -90,848	-74%	-$37M	0.33%	50
2025 Q2	$40M	Sell	122,804 -36,750	-23%	-$10.2M	1.24%	26
2025 Q1	$43.1M	Buy	159,554 +25,795	+19%	+$6.63M	1.35%	24
2024 Q4	$31.5M	Sell	133,759 -5,616	-4%	-$1.48M	1.09%	29
2024 Q3	$38.3M	Sell	139,375 -99,121	-42%	-$25.8M	1.33%	28
2024 Q2	$58M	Buy	238,496 +32,917	+16%	+$5.2M	2.11%	23
2024 Q1	$30.7M	Buy	205,579 +16,438	+9%	+$2.74M	0.97%	29
2023 Q4	$36.2M	Buy	189,141 +77,307	+69%	+$13.2M	1.13%	28
2023 Q3	$19.5M	Buy	111,834 +111,778	+199,604%	+$21.3M	0.63%	33
2023 Q2	$10K	Sell	56 -84	-60%	-$16.7K	﹤0.01%	65
2023 Q1	$28K	Buy	140 +22	+19%	+$4.62K	﹤0.01%	61
2022 Q4	$28K	Buy	+118	New	+$25.2K	﹤0.01%	62